Validation of tissue array technology in head and neck squamous cell carcinoma

Head and Neck

Volumn 25, Issue 11, 2003, Pages 922-930

  Chen, Bei ^a,b   Van den Brekel, Michiel W M ^a   Buschers, Wim ^a   Balm, Alfons J M ^a   Van Velthuysen, Marie Louise F ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Correlation studies; Head and neck neoplasms; Immunohistochemistry; Prognosis; Survival analysis; Tissue arrays

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; PEROXIDASE; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CELL CYCLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; OBSERVER VARIATION; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TISSUE ARRAY TECHNOLOGY; TREATMENT OUTCOME; TUMOR BIOPSY; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLIN D1; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETINOBLASTOMA PROTEIN; STATISTICS, NONPARAMETRIC;

EID: 0142188678     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10308     Document Type: Article

References (21)

1. Blons H, Cabelguenne A, Carnot F, et al. Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. Int J Cancer 1999;84:410-415.
2. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999;5:1966-1975.
3. Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 1999;154:981-986.
4. Takes RP, Baatenburg de Jong RJ, Keuning J, Hermans J, Schuuring E, Van Krieken HJ. Protein expression of cancer associated genes: biopsy material compared to resection material in laryngeal cancer. Anticancer Res 1998;18:4787-4791.
5. Jacob R, Welkoborsky HJ, Mann WJ, Hofken F, Dienes HP, Freije JE. Heterogeneity of squamous cell carcinomas of the head and neck-analysis of tumor biologic factors and proliferation rates. Laryngoscope 1996;106:1170-1175.
6. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-1949.
7. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
8. Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 2000;31:406-414.
9. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001;158:1245-1251.
10. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-2256.
11. Nocito A, Bubendorf L, Maria TE, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194:349-357.
12. van den Brekel MWM, Bindels EMJ, Balm AJM. Prognostic factors in head and neck cancer, editorial comment. Eur J Cancer 2002;38:1041-1043.
13. Tsuda H, Sasano H, Akiyama F, et al. Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma. Pathol Int 2002;52:126-134.
14. Layfield LJ, Saria E, Mooney EE, Liu K, Dodge RR. Tissue heterogeneity of immunohistochemically detected estrogen receptor. Implications for image analysis quantification. Am J Clin Pathol 1998;110:758-764.
15. Adams EJ, Green JA, Clark AH, Youngson JH. Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol 1999;52:75-77.
16. Smith BD, Smith GL, Carter D, et al. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001;127:780-785.
17. Michalides RJ, van Veelen NM, Kristel PM, et al. Over-expression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1997;123:497-502.
18. Yuen PW, Chow V, Choy J, Lam KY, Ho WK, Wei WI. The clinicopathologic significance of p53 and p21 expression in the surgical management of lingual squamous cell carcinoma. Am J Clin Pathol 2001;116:240-245.
19. Jackel MC, Sellmann L, Youssef S, Dorudian MA, Fuzesi L. Prognostic significance of expression of p53, bcl-2 and bax in squamous epithelial carcinoma of the larynx. A multivariate analysis. HNO 2001;49:204-211.
20. Grabenbauer GG, Muhlfriedel C, Rodel F, et al. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1041-1050.
21. Takes RP, Baatenburg de Jong RJ, Schuuring E, Litvinov SV, Hermans J, van Krieken JH. Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anticancer Res 1998;18:4793-4800.